Silencing Prion Protein in HT29 Human Colorectal Cancer Cells Enhances Anticancer Response to Fucoidan

CHUL WON YUN1,2*, SEUNGPIL YUN3*, JUN HEE LEE3, YONG-SEOK HAN1,2, YEO MIN YOON1,2, DANIEL AN3 and SANG HUN LEE1,2

1Medical Science Research Institute, Soonchunhyang University, Seoul Hospital, Seoul, Republic of Korea; 2Department of Medical Bioscience, Soonchunhyang University, Asan, Republic of Korea; 3Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.

Abstract. Background: The putative functions of the cellular prion protein (PrPc) are believed to be associated with cell signaling, differentiation, survival, and cancer progression. With respect to cancer development and progression, elevations and mutations of PrPc expression have been shown to increase the risk for malignancy and metastasis in breast and colorectal cancer. Since both natural supplements and direct regulation of PrPc expression contribute to inhibition of cancer progression and growth, we hypothesized that knockdown of PrPc expression with small-interfering RNA (si-PRNP) could lead to an enhanced synergic effect on the inhibition of cancer growth by fucoidan. Materials and Methods: PrPc expression was suppressed in HT29 human colon cancer cells by utilizing small-interfering RNA (si-PRNP), and cells were subsequently used to study the antiproliferative and anticancer effects of fucoidan treatment of HT29 human colon cancer cells. Results: Fucoidan treatment significantly inhibited growth and reduced cyclin and cyclin-dependent kinase (CDK) expression in HT29 colon cancer cells. Furthermore, silencing PrPc expression with si-PRNP amplified the fucoidan-induced changes in cell proliferation, apoptosis, and migration. Intraperitoneal injection of si-PRNP with fucoidan reduced proliferation and tumor volume in Balb/c nude mice. This enhanced antitumor efficacy was associated with decreased angiogenesis. Conclusion: Combination of fucoidan with silencing of PrPc has a synergic effect on the inhibition of HT29 colon cancer cell growth.

Furthermore, we provide evidence for the therapeutic application of PrPc silencing with other anticancer drugs for cancer.

Developing natural products and dietary supplements has proven to be a promising strategy for the cancer therapy and prevention. Among them, fucoidan, which is isolated from brown seaweed such as Cladosiphon okamuranus and Fucus evanescens (1, 2), is structurally similar to heparin, with a substantial percentage of L-fucose (3, 4). Recent studies have shown its various effects on biological activities such as anti-inflammatory, anti-coagulant (5), anti-HIV, and anticancer (6-9) activities. With respect to cancer therapy, fucoidan appears to be highly efficient in treating certain types of cancer, including breast, prostate and lung, as well as leukemia (10-12). Furthermore, fucoidan can also play a crucial role in inhibiting induced cancer signaling molecules, such as vascular endothelial growth factor (VEGF) (13, 14). Although these results support the potential development of fucoidan as an anticancer drug, there is little information on the anticancer effect of fucoidan on colorectal cancer (CRC).

CRC is the second most commonly diagnosed cancer among females and third among males worldwide. It also contributes significantly to cancer-related deaths, despite continuous progress in developing diagnostic and therapeutic methods (15). It is thought that CRC may be caused by a combination of both genetic susceptibilities and lifestyle factors such as a meat-rich diet (16). Although the discovery of factors that cause CRC give new insights into the growth and metastasis of CRC, there is still little information on the etiology of most CRC, therapeutic agents, and anti-CRC targeting molecules. However, cellular prion protein (PrPc) expression has been identified as a risk or susceptibility factor for developing CRC (17). In essence, PrPc is a highly conserved cell-surface glycoprotein that has been identified in all vertebrates, with the same protein sequence as the prion proteins that cause...
Inhibition of PrP c expression by small RNA interference (Tecan, Männedorf, Switzerland).

Formazan by mitochondrial dehydrogenase. Formazan was quantified 5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2-tetrazolium to determine using a modification of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, which is based on the conversion of the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)subconfluently incubated in 96-well plates with fucoidan siRNA in serum-free Opti-MEM (Gibco BRL) using Lipofectamine (2.5×10^5) cells were seeded in 60 mm dishes and transfected with human CRC cells.

of cancer cells were used to study the cell-cycle of HT29 (PCNA), caspase 3, VEGF, and human cluster of 2000 following the manufacturer's instructions (Thermo Fisher Scientific). At 48 h after transfection, the total protein extracted was determined by western blot analysis. The siRNA used to target PRNP and a scrambled sequence was synthesized by Bioneer (Daejeon, Korea).

Wound-healing migration assay. HT29 cells were seeded onto 60 mm cell culture plate and cultured at 90% confluence in 4 ml of growth medium. The cell layer was scratched using a 2 mm wide tip to make a line-shaped wound and treated with fucoidan (200 μg/ml) alone, siPRNP transfection alone and both treatment for 48 h at 37°C. The cells were allowed to migrate and images were acquired by capturing an inverted microscope (Eclipse TE300, Nikon, Tokyo, Japan).

Ethics statement. Experiments were performed on 8-week-old male BALB/CA-nu/nu mice (Biogenomics, Seoul, Korea; http://www.orient.co.kr). All procedures were performed in accordance with the policies of the Institutional Animal Care and Use Committee of Soonchunhyang University, Seoul Hospital, Korea (IACUC2013-5). Throughout the experiment, all animals were monitored carefully for any distress, pain, or discomfort. All efforts were made to minimize suffering.

Tumor growth in mice. Up to five mice per cage were housed in Macrolon cages and supplied with wooden bedding, shelters, and treadmills. The mice had ad libitum access to drinking water and standard chow. The environmental temperature was regulated at 22°C, with a relative humidity of ±45%. The mice were subjected to a 12/12-h day/night cycle under artificial lighting. The mice were allowed to acclimatize for at least 1 week before intraperitoneal injection of cancer cells. After intraperitoneal injection, body temperature was maintained at 36.5-37.5°C by placing animals on a heated table for 4 h. At the end of the experiment, the mice were anesthetized with 5% isoflurane in O₂/N₂O and euthanized using carbon dioxide (CO₂) at 27 days after implantation. In vivo generation of tumors was accomplished by injection of 5×10⁶ HT29 cells and si-PRNP transfected HT29 cells suspended in 50 μl PBS into the back subcutaneously, respectively. Animal body weight and tumor size were measured and recorded. Tumor size was measured every 2 days in two perpendicular dimensions (a=length, b=width) with a Vernier caliper, and the size recorded as a volume (mm³) as calculated by: a x b x (π/6)³. After the injected tumors reached a size of 8 to 10 mm³, the mice were intraperitoneally injected with normal saline (control; n=9), or 5 mg/kg body weight fucoidan (n=9) every 2 days for a total of nine administrations. A tumor growth curve was then constructed, and data were presented as the mean±SEM. After 27 days of tumor growth, the mice were euthanized and their tumors were excised and weighed. The tumor specimens were fixed in 4% formaldehyde, embedded in paraffin, and cut in 4-μm sections for immunohistochemical analysis.

Propidium iodide (PI)/annexin V flow cytometric analysis. Apoptosis of HT29 cells was assessed with a Cyflow Cube 8 (Partec, Münster, Germany) after staining the cells with annexin V–fluorescein isothiocyanate (FITC) and PI (De Novo Software, Los Angeles, CA, USA). Data analysis was performed using standard FSC Express (De Novo Software).

Western blot analysis. Total protein was extracted using RIPA Lysis Buffer (Thermo Scientific, Rockford, IL, USA). Cell lysates were separated by sodium dodecyl sulfate-polyacrylamide gel
electro-phoresis and proteins were transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 5% skim milk and incubated with primary antibodies against phospho-CDK2, CDK4, cyclin D1, cyclin E, B-cell lymphoma 2 (BCL2), BCL-2-associated X protein (BAX), cleaved caspase-3, cleaved poly [ADP-ribose] polymerase 1 (PARP1), PrP<sup>C</sup> and β-actin (Santa Cruz Biotechnology, Dallas, TX, USA). After incubation of the membranes with peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology), bands were visualized using enhanced chemiluminescence reagents (Amersham Biosciences, Uppsala, Sweden).

Immunohistochemistry. Immunofluorescence staining was performed using primary antibodies against CD31, VEGF, PCNA and caspase-3 (Santa Cruz Biotechnology), as well as secondary antibodies conjugated with Alexa-488 (Life Technologies, Carlsbad, CA, USA). Immunostained slides were imaged by confocal microscopy (Olympus, Tokyo, Japan). The quantitative results are expressed the number of positive cells per field by ANOVA.

Statistical analyses. Quantitative results are expressed as the mean±SEM. All experimental results were analyzed by ANOVA. In some experiments, this was followed by a comparison of the treatment mean with the control using a Bonferroni-Dunn test. p-values less than 0.05 were considered significant.

Results

Treatment with fucoidan inhibits proliferation and increases apoptosis signal pathways of HT29 cells. To assess the effect of fucoidan on the growth of HT29 cells, an MTT assay was performed to measure cell viability following the treatment of HT29 cells with fucoidan (0, 50, 100, and 200 μg/ml) for 24 h. Fucoidan treatment was found to reduce the viability of HT29 cells dose- and time-dependently (Figure 1A and B). In order to investigate the expression levels of cell cycle-regulated proteins in HT29 cells treated with fucoidan, the levels of these proteins, including CDK2, cyclin E, CDK4, and cyclin D1, were confirmed by western blot analysis (Figure 1C-F). The levels of these proteins were significantly reduced after treatment with 200 μg/ml fucoidan in a time-dependent manner, with the maximal effect being observed at 48 h. These results demonstrate that fucoidan inhibits the proliferation of HT29 cells.

Next, in order to investigate the signaling pathways of fucoidan-induced apoptosis, apoptosis-associated proteins were assessed in vitro at different times after treatment with 200 μg/ml fucoidan. The anti-apoptotic protein BCL2 decreased and the pro-apoptotic proteins BAX, cleaved caspase-3, and cleaved PARP1 increased with fucoidan treatment (Figure 2A-D).

Fucoidan-induced inhibition of PrP<sup>C</sup> expression along with si-PRNP treatment enhanced fucoidan-mediated effect of apoptosis and migration. Previous studies have suggested that PrP<sup>C</sup> plays important roles in cancer cell proliferation (20). The results of the western blots indicated that PrP<sup>C</sup> expression was reduced upon fucoidan treatment for 0 to 48 h (Figure 3A). The efficiency of PrP<sup>C</sup> silencing was verified by immunoblot analyses, which demonstrated a significant reduction of PrP<sup>C</sup> expression in si-PRNP-transfected cells (Figure 3B). Indeed, fucoidan significantly increased the percentage of the early and late apoptotic cells to 17.34% compared to the percentage in the control (3.78%). In addition, si-PRNP-transfected cells significantly increased the early and late apoptotic cells to 10.07%. The percentage of apoptotic cells was further increased in populations transfected with si-PRNP and treated with fucoidan (64.36%) (Figure 3C and D).

Cancer cell migration plays a pivotal role in metastasis and tumor remodeling. Thus, we investigated the effect of si-PRNP on fucoidan-treated HT29 cell migration. A scratch wound-healing assay was performed following the treatment of HT29 cells with 200 μg/ml fucoidan for 48 h (Figure 4A and B). HT29 cell migration was significantly reduced in the fucoidan-treated group compared with the untreated group. The migration of cells decreased even more with si-PRNP transfection and treatment with fucoidan than with fucoidan alone.

si-PRNP enhanced fucoidan-induced reduction of proliferation in tumor tissue. In order to further confirm the ability of si-PRNP and fucoidan to reduce proliferation in vivo, immunofluorescent staining was performed on tissue sections of tumors excised 27 days after implantation of HT29 cells or si-PRNP transfected HT29 cells, and the mice were treated with fucoidan. All treatments significantly reduced the number of PCNA-positive cells (Figure 5A and B) and significantly increased the number of caspase-3-positive apoptotic cells (Figure 5C and D) compared with the control. However, these effects were greatest for si-PRNP transfection combined with fucoidan treatment, suggesting that si-PRNP with fucoidan has a strong antitumor effect on the colon cancer model.

si-PRNP enhanced fucoidan-induced inhibition of colon tumor growth in vivo. The pronounced effect that si-PRNP transfection with fucoidan treatment produced on in vitro HT29 cell proliferation suggested that it may also suppress cancerous growth in vivo. In order to verify this hypothesis, we subcutaneously inoculated male Balb/C nude mice with si-PRNP and HT29 colon cancer cells. After implantation, visible tumors had developed at the injection sites (8 to 10 mm<sup>3</sup> in size). As shown in Figure 6A and B, fucoidan reduced the tumor volume in mice but there was a significantly greater decrease in tumor volume in cells treated with both si-PRNP transfection and fucoidan than in cells treated with fucoidan alone.
si-PRNP enhanced fucoidan-induced inhibition of angiogenesis in tumor tissue. To investigate the effect of si-PRNP on fucoidan-induced angiogenesis in vivo, we analyzed the HT29 tumors by immunofluorescent staining to measure the expression of VEGF. Immunofluorescent staining of HT29 tumors showed a decrease in VEGF expression upon si-PRNP and fucoidan treatment (Figure 7A and B). In addition, we evaluated CD31 expression as a measure of tumor vasculature in harvested HT29 tumors.

Discussion

In this study, we demonstrated that fucoidan, that is a natural product used for cancer therapy, interacts with the
suppression of PrP^C to check the growth of CRC. Fucoidan affects CRC growth by inhibition of the cancer cell cycle and induction of cell death. In combination with fucoidan, silencing of PrP^C leads to a greater reduction in cancer cell proliferation and cell motility, as well as tumor angiogenesis. Further study will be needed to explore the underlying molecular mechanisms of how silencing PrP^C diminishes cancer cell growth and increases the susceptibility of cancer cells to fucoidan, as well as to understand how the degree to which PrP^C protein levels are diminished correlates with fucoidan, eventually producing a synergic effect.

Fucoidan has been demonstrated to be a novel therapeutic agent for cancer treatment. Several studies have demonstrated that fucoidan induces cancer cell death through mitochondrial abnormalities, including increased production of mitochondrial reactive oxygen species (21), inhibits tumor angiogenesis via down-regulation of HIF1 and VEGF (14), down-regulates cell cycle-regulated kinase (22), and reduces

Figure 2. Effect of fucoidan on HT29 colon cancer cell apoptosis. HT29 colon cancer cells were treated with fucoidan (200 μg/ml) for different periods of time (0, 24 and 48 h) and the expression of B-cell lymphoma 2 (BCL2) (A), BCL-2-associated X protein (BAX) (B), cleaved caspase-3 (C) and cleaved poly (ADP-ribose) polymerase 1 (PARP1) (D) was detected using western blot analysis. The bar graph demonstrates the quantification of the expression levels as determined from densitometry relative to β-actin. Values represent the means±SEM. **p<0.01 vs. control.
colon cancer cell migration (23), suggesting that fucoidan-affected signaling contributes to the inhibition of cancer development. Although fucoidan is a natural product and an ingredient of dietary supplements responsible for anticancer effects (24), there is a possibility that fucoidan can also control CRC cell growth by modulating the cell cycle and apoptosis. After treatment with fucoidan, the expression of cell cycle-regulatory proteins such as cyclin D1 and E, CDK2, and CDK4 was reduced, indicating the inhibition of cell proliferation. Moreover, proapoptotic BAX, cleaved caspase-3, and cleaved PARP1 increased while BCL2 decreased upon fucoidan treatment of HT29 cells, stimulating cell death. These results are supported by previous studies in which fucoidan inhibited proliferation of myeloid leukemia cell lines, mediated by activation of apoptotic pathways (21). Therefore, our results strongly suggest that fucoidan plays an

Figure 3. Fucoidan-induced inhibition of cellular prion protein (PrPc) expression and small-interfering RNA-PRNP (si-PRNP)-mediated enhancement of apoptosis. A: HT29 colon cancer cells were treated with fucoidan (200 µg/ml) for 24 and 48 h. The activation of PrPc was then analyzed by western blot. B: HT29 colon cancer cells were transfected for 48 h with si-PRNP and then expression of PrPc was analyzed by western blot. C: HT29 colon cancer cells were transfected for 48 h with si-PRNP and then incubated with or without fucoidan for 48 h. The apoptosis of cells was measured using propidium iodide (PI)/annexin V staining and flow cytometric analysis. PI/annexin V double-negative cells were considered live cells, PI-negative/annexin V- positive cells were considered early apoptotic cells, and PI/annexin V double-positive cells were considered late apoptotic cells. D: Standard quantification of PI/annexin V-positive apoptotic cells. Values represent the mean±SEM. **p<0.01 vs. control, ##p<0.01 vs. fucoidan or si-PRNP alone.
important role in HT29 cell-cycle arrest and apoptosis. Further study is needed to ascertain whether alterations in the cell-cycle arrest and apoptosis due to fucoidan may be involved in cancer cell death mechanisms displayed in fucoidan-treated CRC models.

It has been suggested that gain of PrP<sup>C</sup> function may contribute to cancer growth and metastasis in patients with PrP<sup>C</sup>-associated cancer (25, 26). Previous studies on PrP<sup>C</sup> in cancer are generally consistent with the notion that PrP<sup>C</sup> expression increases resistance to cytotoxicity (27-31). One of the ways to eliminate this is via inhibition of glucose by various therapeutic drugs (32). There seems to be a reciprocal or synergic relationship between down-regulation of PrP<sup>C</sup> and cancer drugs. Down-regulation of PrP<sup>C</sup> due to treatments with targeted siRNA leads to a reduction in cancer cell survival (33). Consistent with previous findings in cancer models (33), we found that silencing PrP<sup>C</sup> slightly increased cancer cell death (Figure 3), while fucoidan treatment reduced endogenous PrP<sup>C</sup> levels. Thus, it is conceivable that silencing PrP<sup>C</sup> in cancer cells may be involved, leading to an increase in fucoidan-mediated cancer cell death and susceptibility to apoptosis. Thus, our study intended to test whether silencing PrP<sup>C</sup> was able to enhance fucoidan-induced inhibition of CRC cell proliferation in vitro and in vivo. Our results indicated that the combination of fucoidan and silencing of PrP<sup>C</sup> increased CRC cell death. These observations also suggest that fucoidan and PrP<sup>C</sup> have a reciprocal relationship, and that this relationship plays an important role in fucoidan-induced cell death. However, further mechanistic studies will be essential to establish whether the role of PrP<sup>C</sup> in response to fucoidan may be a consequence of cancer cell death by characterization of PrP<sup>C</sup> knock out mice with and without fucoidan treatment.
Taken together, the results from this study clearly established that fucoidan is effective as an anticancer drug for colorectal cancer. In addition, PrPc silencing in human colon cancer HT29 cells results in elevated responses to fucoidan treatment. These findings may have implications not only for understanding the role of PrPc in colon cancer biology, but also for elucidating the physiological function of PrPc.

**Conflicts of Interest**

The Authors have no conflicts of interest to declare in regard to this study.

**Acknowledgements**

This study was supported by a National Research Foundation (NRF) grant funded by the Korean government (MEST) (2011-0009610) and by the Ministry of Education (2016R 1D A3B0100 7727). The funders had no role in study design, data collection or analysis, the decision to publish, or preparation of the article.

**References**


